(0.54%) 5 074.00 points
(0.42%) 38 228 points
(0.66%) 17 554 points
(0.78%) $79.62
(1.50%) $1.961
(0.67%) $2 326.50
(0.31%) $26.83
(1.62%) $970.40
(-0.07%) $0.932
(-0.08%) $11.02
(-0.10%) $0.798
(-0.67%) $92.64
Live Chart Being Loaded With Signals
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases...
Stats | |
---|---|
Šios dienos apimtis | 23.92M |
Vidutinė apimtis | 0.00 |
Rinkos kapitalizacija | 26.63B |
EPS | $1.250 ( 2023-11-01 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 61.86 |
ATR14 | $0.803 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-06 | Watkins Thomas | Sell | 10 000 | Ordinary Shares |
2023-10-06 | Watkins Thomas | Sell | 8 548 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 23 092 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 31 153 | Stock Option (Right to Buy) |
2023-10-06 | Watkins Thomas | Sell | 10 838 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-89.06 |
Last 100 transactions |
Buy: 244 079 | Sell: 3 988 089 |
Tūris Koreliacija
Horizon Therapeutics PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BOCH | 0.96 |
NWFL | 0.955 |
WLFC | 0.945 |
PPH | 0.944 |
SNY | 0.943 |
DVCR | 0.941 |
SHSP | 0.94 |
ROST | 0.938 |
MGI | 0.937 |
EWEB | 0.937 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GAINL | -0.964 |
QTEK | -0.96 |
FATE | -0.959 |
LNSR | -0.957 |
IMCC | -0.953 |
VS | -0.95 |
QLGN | -0.949 |
WISA | -0.947 |
TOPS | -0.945 |
LHDX | -0.945 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Horizon Therapeutics PLC Koreliacija - Valiuta/Žaliavos
Horizon Therapeutics PLC Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $3.63B |
Bruto pelnas: | $2.71B (74.64 %) |
EPS: | $2.28 |
FY | 2022 |
Pajamos: | $3.63B |
Bruto pelnas: | $2.71B (74.64 %) |
EPS: | $2.28 |
FY | 2021 |
Pajamos: | $3.23B |
Bruto pelnas: | $2.43B (75.37 %) |
EPS: | $2.37 |
FY | 2020 |
Pajamos: | $2.20B |
Bruto pelnas: | $1.67B (75.79 %) |
EPS: | $1.910 |
Financial Reports:
No articles found.
Horizon Therapeutics PLC
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.